Annual EBITDA
-$266.00 M
-$43.73 M-19.68%
31 December 2023
Summary:
Atara Biotherapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$266.00 million, with the most recent change of -$43.73 million (-19.68%) on 31 December 2023. During the last 3 years, it has risen by +$34.72 million (+11.55%). ATRA annual EBITDA is now -2989.04% below its all-time high of -$8.61 million, reached on 31 December 2013.ATRA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$19.51 M
-$3.06 M-18.57%
30 September 2024
Summary:
Atara Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$19.51 million, with the most recent change of -$3.06 million (-18.57%) on 30 September 2024. Over the past year, it has increased by +$47.70 million (+70.97%). ATRA quarterly EBITDA is now -197.40% below its all-time high of $20.03 million, reached on 30 June 2022.ATRA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$123.21 M
+$47.70 M+27.91%
30 September 2024
Summary:
Atara Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$123.21 million, with the most recent change of +$47.70 million (+27.91%) on 30 September 2024. Over the past year, it has increased by +$157.93 million (+56.17%). ATRA TTM EBITDA is now -9488.48% below its all-time high of -$1.28 million, reached on 31 March 2013.ATRA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ATRA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -19.7% | +71.0% | +56.2% |
| 3 y3 years | +11.6% | +76.3% | +61.5% |
| 5 y5 years | -14.0% | +72.4% | +57.7% |
ATRA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -19.7% | +19.7% | -197.4% | +78.5% | at high | +63.9% |
| 5 y | 5 years | -19.7% | +19.7% | -197.4% | +78.5% | at high | +63.9% |
| alltime | all time | -2989.0% | +19.7% | -197.4% | +78.5% | -9488.5% | +63.9% |
Atara Biotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$19.51 M(+18.6%) | -$123.21 M(-27.9%) |
| June 2024 | - | -$16.46 M(-43.6%) | -$170.91 M(-23.4%) |
| Mar 2024 | - | -$29.18 M(-49.7%) | -$222.98 M(-16.2%) |
| Dec 2023 | -$266.00 M(+19.7%) | -$58.06 M(-13.6%) | -$266.00 M(-5.4%) |
| Sept 2023 | - | -$67.21 M(-1.9%) | -$281.14 M(-5.2%) |
| June 2023 | - | -$68.53 M(-5.1%) | -$296.51 M(+42.6%) |
| Mar 2023 | - | -$72.20 M(-1.4%) | -$207.95 M(-6.4%) |
| Dec 2022 | -$222.26 M(-32.9%) | -$73.20 M(-11.4%) | -$222.26 M(-7.4%) |
| Sept 2022 | - | -$82.59 M(-512.3%) | -$239.98 M(+0.0%) |
| June 2022 | - | $20.03 M(-123.2%) | -$239.89 M(-29.8%) |
| Mar 2022 | - | -$86.51 M(-4.8%) | -$341.60 M(+3.2%) |
| Dec 2021 | -$331.12 M(+10.1%) | -$90.92 M(+10.2%) | -$331.12 M(+3.6%) |
| Sept 2021 | - | -$82.50 M(+1.0%) | -$319.74 M(+3.2%) |
| June 2021 | - | -$81.68 M(+7.4%) | -$309.78 M(+1.9%) |
| Mar 2021 | - | -$76.02 M(-4.4%) | -$304.00 M(+1.1%) |
| Dec 2020 | -$300.72 M(+4.2%) | -$79.54 M(+9.7%) | -$300.72 M(+0.6%) |
| Sept 2020 | - | -$72.53 M(-4.4%) | -$298.98 M(+0.6%) |
| June 2020 | - | -$75.90 M(+4.3%) | -$297.22 M(+0.7%) |
| Mar 2020 | - | -$72.75 M(-6.5%) | -$295.12 M(+2.3%) |
| Dec 2019 | -$288.61 M(+23.7%) | -$77.80 M(+9.9%) | -$288.61 M(-0.9%) |
| Sept 2019 | - | -$70.77 M(-4.1%) | -$291.15 M(+4.2%) |
| June 2019 | - | -$73.80 M(+11.4%) | -$279.41 M(+8.5%) |
| Mar 2019 | - | -$66.24 M(-17.5%) | -$257.50 M(+10.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$233.38 M(+93.6%) | -$80.34 M(+36.1%) | -$233.38 M(+23.8%) |
| Sept 2018 | - | -$59.03 M(+13.8%) | -$188.56 M(+17.2%) |
| June 2018 | - | -$51.89 M(+23.2%) | -$160.94 M(+17.7%) |
| Mar 2018 | - | -$42.12 M(+18.6%) | -$136.74 M(+13.4%) |
| Dec 2017 | -$120.58 M(+49.1%) | -$35.52 M(+13.1%) | -$120.58 M(+16.3%) |
| Sept 2017 | - | -$31.41 M(+13.4%) | -$103.63 M(+5.7%) |
| June 2017 | - | -$27.69 M(+6.7%) | -$98.03 M(+9.2%) |
| Mar 2017 | - | -$25.95 M(+39.7%) | -$89.77 M(+11.0%) |
| Dec 2016 | -$80.86 M(+38.5%) | -$18.58 M(-28.0%) | -$80.86 M(-3.8%) |
| Sept 2016 | - | -$25.81 M(+32.9%) | -$84.02 M(+19.2%) |
| June 2016 | - | -$19.42 M(+13.9%) | -$70.46 M(+6.5%) |
| Mar 2016 | - | -$17.05 M(-21.6%) | -$66.14 M(+13.3%) |
| Dec 2015 | -$58.40 M(+107.5%) | -$21.74 M(+77.5%) | -$58.40 M(+23.6%) |
| Sept 2015 | - | -$12.25 M(-18.9%) | -$47.25 M(+15.4%) |
| June 2015 | - | -$15.10 M(+62.3%) | -$40.95 M(+34.8%) |
| Mar 2015 | - | -$9.30 M(-12.2%) | -$30.38 M(+7.9%) |
| Dec 2014 | -$28.15 M(+226.9%) | -$10.59 M(+78.1%) | -$28.15 M(+34.2%) |
| Sept 2014 | - | -$5.95 M(+31.2%) | -$20.97 M(+19.3%) |
| June 2014 | - | -$4.53 M(-35.9%) | -$17.58 M(+22.0%) |
| Mar 2014 | - | -$7.08 M(+107.1%) | -$14.40 M(+67.2%) |
| Dec 2013 | -$8.61 M | -$3.42 M(+33.9%) | -$8.61 M(+65.7%) |
| Sept 2013 | - | -$2.55 M(+87.6%) | -$5.20 M(+96.4%) |
| June 2013 | - | -$1.36 M(+5.8%) | -$2.65 M(+105.8%) |
| Mar 2013 | - | -$1.28 M | -$1.28 M |
FAQ
- What is Atara Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Atara Biotherapeutics?
- What is Atara Biotherapeutics annual EBITDA year-on-year change?
- What is Atara Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Atara Biotherapeutics?
- What is Atara Biotherapeutics quarterly EBITDA year-on-year change?
- What is Atara Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Atara Biotherapeutics?
- What is Atara Biotherapeutics TTM EBITDA year-on-year change?
What is Atara Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ATRA is -$266.00 M
What is the all time high annual EBITDA for Atara Biotherapeutics?
Atara Biotherapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$8.61 M
What is Atara Biotherapeutics annual EBITDA year-on-year change?
Over the past year, ATRA annual earnings before interest, taxes, depreciation & amortization has changed by -$43.73 M (-19.68%)
What is Atara Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ATRA is -$19.51 M
What is the all time high quarterly EBITDA for Atara Biotherapeutics?
Atara Biotherapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $20.03 M
What is Atara Biotherapeutics quarterly EBITDA year-on-year change?
Over the past year, ATRA quarterly earnings before interest, taxes, depreciation & amortization has changed by +$47.70 M (+70.97%)
What is Atara Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ATRA is -$123.21 M
What is the all time high TTM EBITDA for Atara Biotherapeutics?
Atara Biotherapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.28 M
What is Atara Biotherapeutics TTM EBITDA year-on-year change?
Over the past year, ATRA TTM earnings before interest, taxes, depreciation & amortization has changed by +$157.93 M (+56.17%)